EZR and neoplasm: Ad5/3-E2F-d24-vIL2 efficiently counteracted the immunosuppressive human OvCa TME by enhancing NK cell and T lymphocyte cytotoxicity, while maintaining tumor-infiltrating TReg levels comparable to NK cell monotherapy.